The hypothalamus occupies a unique position in pharmacology: it is simultaneously the master regulator of the endocrine system and a source of drug targets whose manipulation produces clinically profound and highly selective effects across oncology, reproductive medicine, endocrinology, and critical care. The releasing and inhibiting hormones synthesized by hypothalamic neurons reach the anterior pituitary via the hypothalamic-pituitary portal circulation, where nanomolar concentrations activate highly specific G protein-coupled receptors (GPCRs) to stimulate or suppress pituitary hormone secretion. Because these peptide hormones have very short plasma half-lives and are active only within the portal microenvironment under physiological conditions, their pharmacological exploitation required the development of structural analogs engineered for prolonged receptor occupancy, oral bioavailability, or selective receptor subtype engagement. This module establishes the physiological and receptor pharmacology foundation that underpins all subsequent modules in this series.
Gonadotropin-releasing hormone (GnRH), also designated luteinizing hormone-releasing hormone (LHRH), is a decapeptide synthesized primarily by approximately 1,000 to 3,000 neurons scattered through the medial preoptic area and arcuate nucleus of the hypothalamus. The GnRH gene encodes a 92-amino-acid precursor (prepro-GnRH) that is cleaved to yield the biologically active GnRH decapeptide (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) plus GnRH-associated peptide (GAP), a 56-amino-acid fragment whose independent biological role remains under investigation.1 GnRH is stored in neurosecretory granules and released in discrete pulses into the hypothalamic-pituitary portal blood, with pulse frequency in reproductive-age adults of approximately one pulse every 60 to 90 minutes during the follicular phase and one pulse every 2 to 4 hours during the luteal phase.
The pulsatile mode of GnRH secretion is not merely a physiological curiosity but a pharmacological principle of critical clinical importance. Pulsatile GnRH stimulation activates pituitary gonadotrophs to synthesize and release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), whereas continuous or sustained GnRH receptor activation, as occurs with GnRH agonist analogs administered by non-pulsatile routes, paradoxically suppresses LH and FSH secretion through receptor downregulation and uncoupling. This is the mechanistic basis for the medical castration achieved by depot GnRH agonists in prostate cancer, endometriosis, and uterine fibroids, and it explains why a clinician who understands GnRH receptor pharmacology can predict the clinical behavior of leuprolide, goserelin, and their congeners from first principles.2
The GnRH receptor (GnRHR) is a seven-transmembrane G protein-coupled receptor (GPCR) that, uniquely among GPCRs, lacks an intracellular carboxyl-terminal tail. This structural feature has direct pharmacological consequences: the absence of the C-terminal tail markedly slows receptor internalization and resensitization, prolonging the duration of receptor-mediated signaling but also making the receptor more susceptible to sustained-stimulation-induced downregulation. GnRHR coupling is primarily through Gq/11 proteins, activating phospholipase C beta (PLC-beta), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes calcium from the endoplasmic reticulum, and DAG activates protein kinase C (PKC), together driving LH and FSH exocytosis and stimulating gonadotropin subunit gene transcription.12
Receptor downregulation under continuous GnRH stimulation proceeds in two phases. In the first phase, within minutes of sustained stimulation, GnRHR undergoes homologous desensitization through PKC-mediated receptor phosphorylation and uncoupling from Gq without significant loss of receptor protein from the cell surface. In the second phase, occurring over hours to days of continuous exposure, receptor internalization proceeds via a clathrin-independent, dynamin-dependent pathway, reducing total surface receptor density by 80 to 95%. This receptor loss, combined with post-receptor signal uncoupling, constitutes the pharmacodynamic basis for GnRH agonist-induced medical castration. Recovery of gonadotropin secretion after cessation of agonist therapy requires weeks to months as surface receptor density is restored, explaining the delayed fertility recovery observed after depot GnRH agonist discontinuation.2
Pulsatile GnRH (1 pulse/60–90 min) stimulates LH and FSH. Continuous GnRH (agonist depot or constant infusion) suppresses LH and FSH via downregulation. This receptor-level distinction explains why GnRH agonists are used both to induce ovulation (short-course pulsatile or single-dose trigger) and to produce medical castration (continuous depot). The route, formulation, and dosing interval determine the pharmacodynamic outcome, not the drug itself.
Thyrotropin-releasing hormone (TRH) is a tripeptide (pyroGlu-His-Pro-NH2) synthesized in the paraventricular nucleus (PVN) of the hypothalamus and released into portal blood to stimulate thyrotroph cells in the anterior pituitary to secrete thyroid-stimulating hormone (TSH). TRH also stimulates prolactin secretion from lactotroph cells, which explains why primary hypothyroidism with chronically elevated TRH can produce hyperprolactinemia and galactorrhea, a clinically recognizable consequence of the cross-reactivity of TRH signaling. The TRH receptor (TRHR) is a G protein-coupled receptor (GPCR) of the Gq subtype; its activation drives phospholipase C beta (PLC-beta)-IP3-DAG signaling identical in mechanism to GnRHR activation, mobilizing intracellular calcium to trigger TSH exocytosis and stimulating TSH alpha and beta subunit gene transcription.
TRH itself has a plasma half-life of approximately 4 to 6 minutes, degraded rapidly by the serum enzyme pyroglutamyl peptidase II, making it unsuitable for therapeutic use in native form. The main clinical pharmacological application of TRH physiology is the TRH stimulation test, historically used to evaluate the hypothalamic-pituitary-thyroid (HPT) axis in equivocal cases of central hypothyroidism. Protirelin (synthetic TRH) given intravenously at 500 mcg produces a measurable TSH rise within 30 minutes in normal individuals; a blunted or absent TSH response indicates pituitary insufficiency, while an exaggerated or delayed response suggests hypothalamic disease with an intact but chronically understimulated pituitary. With the advent of sensitive TSH assays, protirelin stimulation testing is now rarely performed but remains conceptually important for understanding feedback regulation of the HPT axis.4
Corticotropin-releasing hormone (CRH) is a 41-amino-acid peptide synthesized predominantly in the parvocellular neurons of the paraventricular nucleus (PVN) and released into portal blood to drive adrenocorticotropic hormone (ACTH) secretion from pituitary corticotroph cells. CRH acts through two receptor subtypes: CRH receptor type 1 (CRH-R1) and CRH receptor type 2 (CRH-R2), both Gs-coupled GPCRs that activate adenylyl cyclase, raise intracellular cyclic adenosine monophosphate (cAMP), and activate protein kinase A (PKA) to stimulate pro-opiomelanocortin (POMC) gene transcription and ACTH secretion.5 CRH-R1 is the dominant mediator of pituitary ACTH release, while CRH-R2 is expressed more broadly in peripheral tissues including heart, skeletal muscle, and brain, where it modulates stress responses and energy homeostasis.6
The clinical pharmacology of the CRH axis centers on the CRH stimulation test for differential diagnosis of Cushing syndrome (hypercortisolism). Human or ovine CRH (oCRH) administered intravenously at 1 mcg/kg produces an ACTH and cortisol rise that is exaggerated in pituitary-dependent Cushing disease (Cushing disease is caused by an ACTH-secreting pituitary adenoma), blunted or absent in adrenal-dependent Cushing syndrome (adrenal adenoma or carcinoma producing autonomous cortisol), and paradoxically elevated with ectopic ACTH syndrome in some cases, though ectopic tumors are typically CRH-unresponsive. The CRH test is most useful when combined with inferior petrosal sinus sampling (IPSS), where a central-to-peripheral ACTH gradient after CRH stimulation confirms pituitary origin and can lateralize the adenoma.6 CRH-R1 antagonists have been investigated as potential anxiolytic and antidepressant agents, based on the role of CRH in mediating stress responses, though none has advanced to clinical approval to date.
Pituitary Cushing disease: exaggerated ACTH rise after CRH (>35% increase from baseline) because adenoma cells retain some CRH responsiveness. Adrenal Cushing syndrome: no ACTH rise; autonomous adrenal cortisol suppresses CRH-R1 signaling at the pituitary level. Ectopic ACTH: usually no rise (ectopic tumors lack CRH-R1), but rare exceptions exist. A blunted response does not exclude pituitary disease definitively; IPSS is required for definitive localization.
Growth hormone-releasing hormone (GHRH) is a 44-amino-acid peptide (with a biologically active 40-amino-acid N-terminal fragment also present in circulation) synthesized in the arcuate nucleus of the hypothalamus. GHRH binds a Gs-coupled G protein-coupled receptor (GPCR) on pituitary somatotroph cells, activating adenylyl cyclase to raise intracellular cyclic adenosine monophosphate (cAMP), activating protein kinase A (PKA), and stimulating both growth hormone (GH) gene transcription and GH exocytosis. Unlike GnRH, whose pulsatility is generated by an intrinsic hypothalamic pulse generator, GH pulsatility results from the alternating action of episodic GHRH stimulation (generating GH pulses) superimposed on a tonic somatostatin inhibitory tone (suppressing basal GH secretion between pulses). The greatest GH secretory burst normally occurs during slow-wave sleep, a clinically relevant fact because disrupted sleep architecture reduces GH output and contributes to the growth failure seen in sleep-disordered pediatric patients.7
Somatostatin (somatotropin release-inhibiting factor, SRIF) exists in two biologically active forms: somatostatin-14 and somatostatin-28, both derived by differential cleavage of the 116-amino-acid preprosomatostatin precursor. Somatostatin-14 predominates in hypothalamic neurons projecting to the median eminence, while somatostatin-28 is the dominant form in peripheral tissues including the gastrointestinal (GI) tract and pancreas. Both forms are rapidly degraded in plasma by peptidases with half-lives of 1 to 3 minutes, making native somatostatin unsuitable for therapeutic use without structural modification. This pharmacokinetic liability directly drove the development of the somatostatin analog class.8
Somatostatin exerts its biological effects through five receptor subtypes designated somatostatin receptor subtype 1 through 5 (SSTR1 through SSTR5), all of which are Gi-coupled GPCRs. Gi activation inhibits adenylyl cyclase, reducing intracellular cAMP; additionally, somatostatin receptor (SSTR) activation opens inwardly rectifying potassium channels (hyperpolarizing the cell) and inhibits voltage-gated calcium channels, collectively suppressing hormone secretion. The SSTR subtypes are differentially expressed across tissues: SSTR2 (subtype 2) and SSTR5 (subtype 5) predominate on pituitary somatotroph cells and are the primary mediators of GH suppression; SSTR2 is the dominant subtype on most GH-secreting pituitary adenomas (somatotrophinomas); SSTR3 (subtype 3) mediates antiproliferative and pro-apoptotic signaling in tumor cells; SSTR1 (subtype 1) and SSTR4 (subtype 4) are expressed in brain and other peripheral tissues. The subtype selectivity profile of each somatostatin analog determines its clinical utility: octreotide and lanreotide selectively target SSTR2 and SSTR5 (SSTR2/SSTR5-selective agents), while pasireotide is a pan-receptor agonist with high affinity for SSTR1, SSTR2, SSTR3, and SSTR5.89
Beyond GH suppression, somatostatin receptors mediate a broad range of inhibitory effects across the gastrointestinal, pancreatic, and immune systems. In the GI tract, SSTR activation suppresses gastrin, secretin, cholecystokinin (CCK), vasoactive intestinal peptide (VIP), and glucagon-like peptide-1 (GLP-1) secretion; reduces intestinal motility; and decreases splanchnic blood flow. In the pancreas, SSTR2/SSTR5 (SSTR2/5) activation on alpha cells inhibits glucagon secretion, and SSTR5 on beta cells can inhibit insulin secretion, explaining the hyperglycemia observed with somatostatin analogs. These peripheral actions translate directly into the therapeutic applications of somatostatin analogs beyond pituitary disease, including carcinoid syndrome, VIPoma, glucagonoma, and variceal hemorrhage management.8
SSTR2/5 selectivity (octreotide, lanreotide): effective GH suppression in most acromegaly; modest glucose impact because beta-cell SSTR5 blockade is partial. SSTR1/2/3/5 pan-agonism (pasireotide): superior GH/IGF-1 control in SSTR2-poor tumors and Cushing disease (pituitary corticotrophs express SSTR5 > SSTR2); substantially higher hyperglycemia incidence (73% vs. 20–30% with octreotide/lanreotide) because SSTR5-mediated insulin suppression is more pronounced. Subtype expression profiling of pituitary tumors can predict analog response before treatment initiation.
Dopamine functions as a hypothalamic inhibiting hormone through the tuberoinfundibular dopaminergic (TIDA) pathway, in which dopaminergic neurons originating in the arcuate nucleus project to the median eminence and release dopamine directly into the portal circulation. At the anterior pituitary, dopamine binds dopamine type 2 receptors [D2R] on lactotroph cells, activating Gi proteins that inhibit adenylyl cyclase, reduce intracellular cAMP, and suppress both prolactin gene transcription and prolactin secretion. Dopamine is therefore not merely a neurotransmitter in this context but the primary physiological inhibitor of prolactin, which is the only major anterior pituitary hormone under predominantly inhibitory rather than stimulatory hypothalamic control. This distinction is clinically essential: any drug or condition that reduces hypothalamic dopamine synthesis, blocks dopamine transport to the portal blood, or antagonizes D2R at the pituitary will elevate prolactin, explaining drug-induced hyperprolactinemia as a class effect of antipsychotics, metoclopramide, domperidone, and many other D2R antagonists.10
Drug-induced hyperprolactinemia deserves systematic treatment because it is one of the most clinically relevant drug-drug interactions in endocrinology. Antipsychotics (both first-generation agents such as haloperidol and most second-generation agents such as risperidone) block pituitary D2R and reliably elevate prolactin, causing galactorrhea, amenorrhea, and hypogonadism in women, and sexual dysfunction and gynecomastia in men. Among second-generation antipsychotics, clozapine, quetiapine, and aripiprazole are prolactin-sparing; aripiprazole is actually a partial D2R agonist at the pituitary level and can normalize prolactin when added to a prolactin-elevating antipsychotic regimen. Metoclopramide and domperidone elevate prolactin through the same D2R mechanism; verapamil causes hyperprolactinemia through a distinct mechanism (interference with dopamine release rather than receptor blockade); and high-dose opioids suppress hypothalamic dopamine neuron activity through mu-opioid receptor activation, contributing to opioid-induced endocrinopathy.10
Oxytocin and vasopressin (antidiuretic hormone, ADH) are nonapeptides synthesized in magnocellular neurons of the supraoptic nucleus (SON) and paraventricular nucleus (PVN) of the hypothalamus, transported axonally to the posterior pituitary (neurohypophysis), and stored in Herring bodies for release directly into the systemic circulation (not the portal system). Oxytocin acts at the oxytocin receptor (OTR), a Gq-coupled G protein-coupled receptor (GPCR) expressed on uterine myometrial cells, mammary myoepithelial cells, and widely in the brain. Myometrial OTR density increases markedly at term gestation due to estrogen-driven upregulation, explaining why uterine sensitivity to oxytocin rises sharply near delivery. Synthetic oxytocin (Pitocin) for labor induction and augmentation, carbetocin (a long-acting oxytocin analog with t1/2 approximately 40 minutes versus 3 to 5 minutes for native oxytocin), and atosiban (an OTR antagonist used as a tocolytic in preterm labor in Europe) all act at the same receptor.11
Vasopressin (ADH) pharmacology, while centered on the renal collecting duct and vascular smooth muscle, originates in hypothalamic synthesis and merits foundational coverage here. ADH acts through three receptor subtypes: vasopressin receptor type 1a (V1a) receptors (Gq-coupled, vascular smooth muscle contraction and platelet aggregation), vasopressin receptor type 1b (V1b) receptors, also designated vasopressin type 3 (V3) receptors (Gq-coupled, anterior pituitary adrenocorticotropic hormone (ACTH) release), and vasopressin receptor type 2 (V2) receptors (Gs-coupled, renal collecting duct aquaporin-2 water channel insertion, antidiuresis). The pharmacological relevance of this receptor distribution is extensive: desmopressin (DDAVP), a synthetic ADH analog with selective V2 agonism and negligible vasopressin type 1 (V1) activity, avoids vasoconstriction while providing antidiuresis for diabetes insipidus and hemostatic effects (via von Willebrand factor release) for bleeding disorders; vasopressin itself (V1a plus V2 agonist) is used in septic shock to restore vascular tone; and tolvaptan/conivaptan, selective V2 and non-selective V1 plus V2 antagonists (vaptans), are used for hyponatremia management in syndrome of inappropriate antidiuretic hormone secretion (SIADH).
D2R antagonists (antipsychotics, metoclopramide, domperidone): all elevate prolactin. Prolactin-sparing antipsychotics: clozapine, quetiapine, aripiprazole. Verapamil: elevates prolactin via dopamine release interference. Opioids (chronic): suppress TIDA (tuberoinfundibular dopaminergic) neuron firing via mu receptors. Treatment: switch to prolactin-sparing agent if clinically feasible; cabergoline can be added but carries the risk of worsening the underlying psychiatric condition if the patient is on antipsychotics for psychosis.
Native hypothalamic peptides are pharmacologically untenable as therapeutic agents in their unmodified forms for three principal reasons: extremely short plasma half-lives (seconds to minutes) due to rapid peptidase cleavage, negligible oral bioavailability because peptide bonds are hydrolyzed in the gastric and intestinal lumen before absorption, and rapid receptor desensitization at the concentrations achievable with exogenous native peptide dosing. Analog design strategies address each of these limitations through specific structural modifications, and understanding these strategies explains why particular analogs have the clinical properties they do rather than requiring rote memorization of each drug's pharmacokinetics.12
Half-life extension is achieved through several structural approaches. Substitution of D-amino acids (particularly D-amino acids at position 6 of GnRH) at peptidase-susceptible cleavage sites prevents enzymatic recognition and degradation, extending the plasma half-life of GnRH analogs from 2 to 4 minutes (native GnRH) to 3 to 8 hours (leuprolide, buserelin) or longer. C-terminal amidation (replacing the free carboxyl terminus with an amide) further retards carboxy-peptidase attack. For octreotide, the natural cyclic disulfide structure of somatostatin-14 was used as a template, with a four-amino-acid cyclic octapeptide engineered with D-phenylalanine (D-Phe) and D-tryptophan (D-Trp) substitutions at key positions, yielding a molecule with a plasma half-life of approximately 1.7 to 2 hours (subcutaneous injection) compared with 1 to 3 minutes for native somatostatin.12
Depot formulation technology was the second critical innovation enabling once-monthly or once-quarterly dosing of otherwise short-acting peptide analogs. Poly(lactic-co-glycolic acid) (PLGA) microsphere technology encapsulates leuprolide acetate or octreotide in biodegradable polymer microspheres that hydrolyze slowly after intramuscular or subcutaneous injection, releasing drug at a controlled rate over 28 to 90 days. For lanreotide, a distinct deep subcutaneous autogel technology was developed in which the drug self-assembles into a semisolid depot at the injection site, releasing over approximately 28 days without the need for reconstitution. Goserelin is formulated as a rod-shaped biodegradable implant (GoZoladex implant) placed subcutaneously in the anterior abdominal wall, releasing drug over 28 or 84 days. These formulations convert drugs that would otherwise require continuous intravenous infusion or multiple daily injections into convenient outpatient monthly or quarterly administrations.12
Achieving oral bioavailability for peptide-based drugs required more fundamental structural departures from the native peptide template. The oral GnRH antagonists elagolix, relugolix, and linzagolix are non-peptide small molecules designed to competitively block the GnRH receptor without the peptide backbone that confers gastrointestinal (GI) degradability and poor membrane permeability. Elagolix is a non-peptide GnRH receptor antagonist with oral bioavailability of approximately 57%, a short plasma half-life of 4 to 6 hours enabling dose-dependent partial or full hypothalamic-pituitary-gonadal (HPG) axis suppression, and metabolism predominantly via cytochrome P450 3A4 (CYP3A4) with secondary contribution from CYP2C8 (cytochrome P450 2C8). Relugolix has oral bioavailability of approximately 12% but achieves pharmacodynamically effective concentrations; it is a substrate and moderate inhibitor of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), generating clinically important drug-drug interactions with P-gp inhibitors (which can markedly increase relugolix exposure). These oral antagonists achieve immediate testosterone suppression without the initial luteinizing hormone (LH) surge (flare) that characterizes GnRH agonist initiation.3
D-amino acid substitution at peptidase cleavage sites: extends half-life (leuprolide, buserelin, octreotide). C-terminal amidation: prevents carboxy-peptidase degradation. PLGA microsphere depot: converts hours half-life into monthly dosing (leuprolide LAR, octreotide LAR). Non-peptide small molecule design: achieves oral bioavailability by eliminating the peptide backbone (elagolix, relugolix, macimorelin). Receptor subtype selectivity engineering: SSTR2/5 selectivity (octreotide, lanreotide) vs. pan-SSTR agonism (pasireotide) by varying amino acid residues at receptor-contact positions.
The hypothalamic hormones covered in this module serve as the mechanistic foundation for four distinct areas of clinical pharmacology developed in the subsequent modules of this series. GnRH analog pharmacology (Hypothal-02) encompasses the full range of GnRH agonist and antagonist agents, with detailed absorption, distribution, metabolism, and excretion (ADME) profiles, depot formulation pharmacokinetics, and clinical applications across prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The pulsatile versus continuous stimulation principle established in Section 1 of this module is the organizing framework for the entire clinical chapter. Readers should note that GnRH analog use in assisted reproductive technology (ART) is covered in detail in Ova-03 and Ova-04 of the Gonadal and Ovarian Pharmacology series and is not duplicated in Hypothal-02, which focuses on the non-ART indications.
Growth hormone (GH) axis pharmacology (Hypothal-03) applies the growth hormone-releasing hormone (GHRH) receptor and somatostatin receptor subtype pharmacology established here to the clinical drugs: somatostatin analogs (octreotide, lanreotide, pasireotide) with full ADME, somatostatin receptor (SSTR) subtype selectivity, metabolic adverse effects, and drug interactions; GHRH analogs (sermorelin, tesamorelin); GH secretagogue receptor (GHSR) agonists (macimorelin for diagnostic use); GH replacement with somatropin; and pegvisomant, the GH receptor antagonist whose mechanism is entirely distinct from SSTR-mediated GH suppression and whose monitoring requires insulin-like growth factor-1 (IGF-1) rather than GH measurement. Pituitary adenoma pharmacotherapy (Hypothal-04) applies dopamine type 2 receptor (D2R) pharmacology from Section 4 of this module to prolactinoma management, extends SSTR pharmacology to acromegaly treatment algorithms, and introduces the steroidogenesis inhibitors used for Cushing disease, which act downstream of corticotropin-releasing hormone (CRH)-adrenocorticotropic hormone (ACTH) axis stimulation rather than at the hypothalamic level directly.10
Several overarching drug-drug interaction patterns established in this module merit emphasis because they recur throughout the series. First, any drug that antagonizes D2R in the pituitary or reduces tuberoinfundibular dopaminergic (TIDA) pathway activity will elevate prolactin and may counteract dopamine agonist therapy for prolactinoma. Second, drugs that alter cytochrome P450 3A4 (CYP3A4) activity will significantly affect the plasma levels of elagolix, relugolix, and several other oral GnRH-axis agents. Third, the hyperglycemia risk of somatostatin analogs, particularly pasireotide, means that oral hypoglycemic agents and insulin regimens may require adjustment when these drugs are initiated; the mechanism is SSTR5 (somatostatin receptor subtype 5)-mediated insulin suppression combined with SSTR2 (somatostatin receptor subtype 2)-mediated glucagon suppression, with the net effect being impaired insulin secretion relative to glucose load. Finally, the QT interval (QT)-prolonging potential of some hypothalamic axis drugs (discussed in detail in subsequent modules) requires awareness of concurrent QT-prolonging medications, particularly in patients on antiarrhythmic agents or other drugs with known QT effects.
The feedback loops governing each hypothalamic-pituitary axis provide both the pharmacological rationale for drugs and the basis for interpreting laboratory tests used to monitor therapy. In the hypothalamic-pituitary-gonadal (HPG) axis, falling estrogen and testosterone levels during GnRH agonist therapy remove negative feedback at both hypothalamic and pituitary levels; the residual GnRH receptor downregulation overrides this disinhibited feedback, sustaining gonadotropin suppression. In the hypothalamic-pituitary-thyroid (HPT) axis, adequate levothyroxine replacement in hypothyroidism reduces thyrotropin-releasing hormone (TRH) drive by restoring negative thyroid hormone feedback; failure of thyroid-stimulating hormone (TSH) to suppress with levothyroxine suggests either non-compliance, malabsorption, or ongoing hypothalamic TRH hypersecretion. In the hypothalamic-pituitary-adrenal (HPA) axis, the cortisol response to the metyrapone or CRH stimulation test depends on intact hypothalamic CRH secretion and pituitary ACTH responsiveness, and blunted responses identify the level of axis failure. Connecting the receptor pharmacology to laboratory interpretation is a high-yield skill for clinical vignettes across endocrinology.46
HPG (hypothalamic-pituitary-gonadal) axis: low LH/FSH + low sex steroids = central (GnRH or gonadotropin failure) vs. high LH/FSH + low sex steroids = primary gonadal failure. HPT (hypothalamic-pituitary-thyroid) axis: high TSH + low T4 = primary hypothyroidism; low TSH + low T4 = central hypothyroidism (TRH or TSH deficiency). HPA (hypothalamic-pituitary-adrenal) axis: low ACTH + low cortisol = adrenal failure or exogenous steroid suppression; high ACTH + low cortisol = primary adrenal insufficiency; high ACTH + high cortisol = Cushing disease or ectopic ACTH. Each pattern maps to a specific level of hypothalamic-pituitary-peripheral axis dysfunction and guides both diagnostic workup and pharmacological intervention.
Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004;25(2):235–275.
doi:10.1210/er.2003-0002Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. N Engl J Med. 1991;324(2):93–103.
doi:10.1056/NEJM199101103240205Shore ND, Saad F, Cookson MS, et al; HERO Study Investigators. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187–2196.
doi:10.1056/NEJMoa2004325Scanlon MF, Weightman DR, Shale DJ, et al. Dopamine is a physiological regulator of thyrotrophin (TSH) secretion in normal man. Clin Endocrinol (Oxf). 1979;10(1):7–15.
doi:10.1111/j.1365-2265.1979.tb03028.xVale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981;213(4514):1394–1397.
doi:10.1126/science.6267699Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526–1540.
doi:10.1210/jc.2008-0125Muller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev. 1999;79(2):511–607.
doi:10.1152/physrev.1999.79.2.511Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157–198.
doi:10.1006/frne.1999.0183Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–884.
doi:10.1016/S2213-8587(14)70169-XMolitch ME. Drugs and prolactin. Pituitary. 2008;11(2):209–218.
doi:10.1007/s11102-008-0106-6Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629–683.
doi:10.1152/physrev.2001.81.2.629Veber DF, Holly FW, Nutt RF, et al. Highly active cyclic and bicyclic somatostatin analogues of reduced ring size. Nature. 1979;280(5722):512–514.
doi:10.1038/280512a0